Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Wellgistics Health Inc ( (WGRX) ) has issued an update.
On December 8, 2025, Wellgistics Health, Inc. announced the commercial launch of its diabetes drug Brenzavvy® to its network of over 6,500 independent pharmacies. Targeting the $16 billion SGLT-2 inhibitor market, this launch aims to provide cost-effective treatment for 33 million type II diabetics in the U.S., especially those uninsured or underinsured. The initiative leverages the company’s EinsteinRx™ AI platform to educate pharmacists and providers on the benefits of Brenzavvy compared to existing market leaders like Jardiance®. This move is expected to enhance patient care and establish a new model for reformulated drugs, potentially increasing Wellgistics’ market share and providing new revenue opportunities for pharmacists.
More about Wellgistics Health Inc
Wellgistics Health, Inc. is a leader in health information technology, specializing in pharmacy dispensing optimization through its proprietary EinsteinRx™ AI platform and PharmacyChain™ blockchain-enabled smart contracts. The company connects over 6,500 pharmacies and 200 manufacturers, offering services like wholesale distribution, digital prescription routing, and AI-powered hub services to enhance patient access in the U.S. prescription drug market.
Average Trading Volume: 14,301,209
Technical Sentiment Signal: Strong Sell
Current Market Cap: $50.87M
Find detailed analytics on WGRX stock on TipRanks’ Stock Analysis page.